Nielsen Ulrik B. 4
4 · MERRIMACK PHARMACEUTICALS INC · Filed Sep 15, 2017
Insider Transaction Report
Form 4
Nielsen Ulrik B.
SVP and CSO
Transactions
- Sale
Common Stock
2017-09-14$14.20/sh−100$1,420→ 22,681 total - Exercise/Conversion
Common Stock
2017-09-15$13.20/sh+663$8,752→ 30,477 total - Award
Stock Option (right to buy)
2017-09-13+7,500→ 7,500 totalExercise: $13.99Exp: 2027-09-12→ Common Stock (7,500 underlying) - Exercise/Conversion
Stock Option (right to buy)
2017-09-15−663→ 0 totalExercise: $13.20Exp: 2017-10-04→ Common Stock (663 underlying) - Exercise/Conversion
Common Stock
2017-09-14$13.20/sh+100$1,320→ 22,781 total - Exercise/Conversion
Common Stock
2017-09-15$13.20/sh+7,133$94,156→ 29,814 total - Exercise/Conversion
Stock Option (right to buy)
2017-09-14−100→ 7,133 totalExercise: $13.20Exp: 2017-10-04→ Common Stock (100 underlying) - Sale
Common Stock
2017-09-15$14.23/sh−7,796$110,937→ 22,681 total - Exercise/Conversion
Stock Option (right to buy)
2017-09-15−7,133→ 0 totalExercise: $13.20Exp: 2017-10-04→ Common Stock (7,133 underlying)
Footnotes (2)
- [F1]This option is fully vested.
- [F2]This option was previously reported as covering 3,378 shares of common stock at an exercise price of $2.59 per share, but was adjusted to reflect both the special cash dividend that was payable on May 26, 2017 and the reverse stock split that became effective for trading purposes on September 6, 2017.